Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy

COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State

(2021) James M. Tesoriero et al.   JAMA Network Open

Safety and antibody response to the first dose of SARS-CoV-2 messenger RNA vaccine in persons with HIV

(2021) Jake A. Ruddy et al.   AIDS

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

(2021) Joana Barros-Martins et al.   NATURE MEDICINE

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

(2021) Shabir A Madhi et al.   Lancet HIV

Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV

(2021) Emma Touizer et al.   Lancet HIV

Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City

(2020) Keith Sigel et al.   CLINICAL INFECTIOUS DISEASES

Coronavirus disease 2019 (COVID‐19) outcomes in HIV/AIDS patients: a systematic review

(2020) TJ Cooper et al.   HIV MEDICINE

Factors associated with COVID-19-related death using OpenSAFELY

(2020) Elizabeth J. Williamson et al.   NATURE

Reappearance of effector T cells is associated with recovery from COVID-19

(2020) Ivan Odak et al.   EBioMedicine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform

(2020) Krishnan Bhaskaran et al.   Lancet HIV